Austin

Lumos Pharma to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 10, 2021
UCB, Webcast, Investor, Disease, Degenerative disease, NEA, New Enterprise Associates, Therapy, Patient, FDA, Drug development, Orphan, Sales, Pharmaceutical industry

To schedule a meeting with management during the conferences, please contact your salesperson at the respective firm.

Key Points: 
  • To schedule a meeting with management during the conferences, please contact your salesperson at the respective firm.
  • Webcasts for each presentation will be available on the Companys website under Events & Presentations in the Investors & Media section.
  • Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases.
  • If approved by the FDA, LUM-201 would provide an orally administered alternative to recombinant growth hormone injections that PGHD patients otherwise endure for many years of treatment.

Bumble Inc. Announces Third Quarter 2021 Results

Retrieved on: 
Wednesday, November 10, 2021

AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Bumble Inc. (NASDAQ: BMBL), the parent company of Bumble and Badoo, today reported financial results for the third quarter ended September 30, 2021.

Key Points: 

Ideal Power Reports Third Quarter 2021 Financial Results

Retrieved on: 
Wednesday, November 10, 2021
UPS, Innovation, DTI, SBIR, Renewable energy, Department, Burns, DC, Research, Program, Partnership, Primary energy, EV, DOE, GLOBE, Solution, AC, NAVSEA, Marketing, Diversified Technology, Television, Management, Pharmaceutical industry, Fireworks, Lithium, Animal

AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ideal Power Inc. (Ideal Power or the Company) (Nasdaq: IPWR), pioneering the development and commercialization of highly efficient and broadly patented B-TRAN bidirectional power switches, reported results for its third quarter ended September 30, 2021.

Key Points: 
  • AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ideal Power Inc. (Ideal Power or the Company) (Nasdaq: IPWR), pioneering the development and commercialization of highly efficient and broadly patented B-TRAN bidirectional power switches, reported results for its third quarter ended September 30, 2021.
  • Grant revenue was $121,028 in the third quarter of 2021 compared to $147,787 in the third quarter of 2020.
  • Ideal Power had no long-term debt outstanding at September 30, 2021.
  • Ideal Power President and CEO Dan Brdar and CFO Tim Burns will host a conference call today, followed by a question-and-answer period.

Workweek Announces Launch of Creator-First B2B Media Company

Retrieved on: 
Wednesday, November 10, 2021
Science and technology in Asia, Contract, Creator's Bill of Rights, Founder, Parental leave, Income, Advertising, YouTube, Sherman, GLOBE, B2B, KPI-driven code analysis, PTO, The Wall Street Journal, Cannabis, Omnichannel, Sleep, Marketing, Public relations, Creative industries

AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Workweek , a "creator-first"B2B media company intended to reshape the traditional media company model by offering unprecedented support and benefits to emerging content creators, launches today.

Key Points: 
  • AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Workweek , a "creator-first"B2B media company intended to reshape the traditional media company model by offering unprecedented support and benefits to emerging content creators, launches today.
  • Founded by media industry veterans Adam Ryan and Becca Sherman, Workweek will infuse media into every sector of the business world.
  • To date, Ryan and Sherman have brought on creators in healthcare, cannabis, fintech, and the media industry.
  • "Traditionally, a great creator at a media company increases brand value, user growth, revenue per user, and many other KPIs across the business.

Human trafficking awareness and prevention exhibition available to travel across Texas starting in January 2022

Retrieved on: 
Wednesday, November 10, 2021
Bullock Texas State History Museum, Museum, Organization, Friends, Survivor, National Center for Missing & Exploited Children, Â, Bangladesh Technical Education Board, Fight Against Coercive Tactics Network, Bullock, Mission, Association, Thought, GLOBE, Awareness, National Center for Civil and Human Rights, McCain Institute, School, Library, Working Together, National Action Plan to Combat Human Trafficking, Exhibition, Sex industry

Austin, TX, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Starting in January 2022, the Bullock Texas State History Museum will offer a traveling version of its groundbreaking exhibition Not Alone: Working Together in the Fight Against Human Trafficking .

Key Points: 
  • Austin, TX, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Starting in January 2022, the Bullock Texas State History Museum will offer a traveling version of its groundbreaking exhibition Not Alone: Working Together in the Fight Against Human Trafficking .
  • The exhibition is available to organizations across Texas free-of-charge for a display period of up to five weeks, thanks to funding from Nancy Ann and Ray L. Hunt, the Texas Trucking Association, and the Texas Bar Foundation.
  • "The most important thing is prevention," said Kristen Abrams, Senior Director of Combatting Human Trafficking at the McCain Institute.
  • Texas venues interested in reserving Not Alone: Working Together in the Fight Against Human Trafficking can contact the Bullock Museum at [email protected].

Cassava Sciences Reports Third Quarter 2021 Financial Results

Retrieved on: 
Wednesday, November 10, 2021
Cognition, Safety, Neuroscience, Private Securities Litigation Reform Act, G&A, Drug development, News, Clinical trial, R, National, Insurance, Depreciation, COVID-19, Research, Annual report, Intention, GLOBE, Solution, SEC, Nasdaq, NIH, Risk, Cryptocurrency, Pharmaceutical industry, Air cargo

AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today announced financial results for the third quarter ended September 30, 2021.

Key Points: 
  • AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today announced financial results for the third quarter ended September 30, 2021.
  • At September 30, 2021, cash and cash equivalents were $241.5 million, compared to $93.5 million at December 31, 2020, with no debt.
  • Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimers disease.
  • Our clinical results from earlier-stage clinical trials may not be indicative of full results or results from later-stage or larger scale clinical trials and do not ensure regulatory approval.

Aspira Women’s Health Reports Third Quarter 2021 Financial Results

Retrieved on: 
Wednesday, November 10, 2021
Medical school, Population, Mirna, Ovarian cancer, ALL, Food, Growth, COVID-19, Risk assessment, Risk, CA125, Genetics, Depression, Technology, Research, Criticism of the Food and Drug Administration, AIM, Element, Woman, Travel, Conference, GLOBE, Dana–Farber Cancer Institute, Marketing, Patient, FDA, Phase II, LDT, Webcast, Concept, Employment, Medicaid, Dana, Consultant, Hospital, Investment, Algorithm, Medical University of Łódź, Conference call, Silviculture, Pharmaceutical industry, Birth control, Health insurance, Video game, Lithium, Animal

AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the third quarter ended September 30, 2021.

Key Points: 
  • ET
    AUSTIN, Texas, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Aspira Womens Health Inc. (Aspira) (Nasdaq: AWH), a bio-analytical based womens health company focused on gynecologic disease, today reported its financial results for the third quarter ended September 30, 2021.
  • Quarter over Quarter Results Third Quarter of 2021 versus Third Quarter of 2020:
    Quarter over Quarter Results Third Quarter 2021 versus Second Quarter 2021:
    Total product and genetics revenue decreased 7% to $1,663,000 down from $1,797,000 in the second quarter of this year.
  • Highlights of Third Quarter 2021 vs. Second Quarter 2021:
    Product revenue was $1,614,000 for the three months ended September 30, 2021, compared to $1,718,000 for the second quarter of 2021, a decrease of 6%.
  • Cash used in operations in the third quarter of 2021 was $7.9 million compared to $6.5 million in the second quarter of 2021.

BOXX Systems Now Offer NVIDIA Omniverse Enterprise

Retrieved on: 
Tuesday, November 9, 2021
Cloud, Efficiency, Autodesk Revit, Industry, Omniverse, Engineering, Knowledge, Technology, NVIDIA, Architecture, Deep learning, Arnold, GLOBE, Marketing, Computing, GTC, Solution, Animation, Video game console, Creative industries

By offering NVIDIA Omniverse Enterprise, BOXX will empower customers with real-time collaboration regardless of geographical distance, significantly improving efficiency and reducing costs.

Key Points: 
  • By offering NVIDIA Omniverse Enterprise, BOXX will empower customers with real-time collaboration regardless of geographical distance, significantly improving efficiency and reducing costs.
  • Our dedication to facilitating remote work for creators, along with the innovative integration of NVIDIA GPUs, makes our adoption of NVIDIA Omniverse Enterprise an easy decision, said Bill Leasure, BOXX VP of Sales and Marketing.
  • With NVIDIA Omniverse Enterprise, BOXX systems will unite and enable these creators to work simultaneously and run graphics-intensive applications from anywhere without sacrificing performance.
  • For further information and pricing on BOXX solutions with NVIDIA Omniverse Enterprise, contact a BOXX sales consultant in the US at 1-877-877-2699.